The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Oncotarget Année : 2015

The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value

Résumé

The recently described oncogene ZNF217 belongs to a chromosomal region that is frequently amplified in human cancers. Recent findings have revealed that alternative mechanisms such as epigenetic regulation also govern the expression of the encoded ZNF217 protein. Newly discovered molecular functions of ZNF217 indicate that it orchestrates complex intracellular circuits as a new key regulator of tumorigenesis. In this review, we focus on recent research on ZNF217-driven molecular functions in human cancers, revisiting major hallmarks of cancer and highlighting the downstream molecular targets and signaling pathways of ZNF217. We also discuss the exciting translational medicine investigating ZNF217 expression levels as a new powerful biomarker, and ZNF217 as a candidate target for future anti-cancer therapies.
Fichier principal
Vignette du fichier
The dark side ZNF Oncotarget 2015.pdf (2.01 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

inserm-01427161 , version 1 (05-01-2017)

Identifiants

Citer

Pascale A Cohen, Caterina F Donini, Nhan T Nguyen, Hubert F Lincet, Julie A Vendrell. The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value. Oncotarget, 2015, 6 (39), pp.41566-81. ⟨10.18632/oncotarget.5893⟩. ⟨inserm-01427161⟩
79 Consultations
246 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More